


# **SSG-resistance of *Leishmania (Leishmania) donovani* - relation with fitness of the parasite and influence on other treatments**

Dissertation for the degree of Doctor in Biomedical Sciences  
at the University of Antwerp to be defended by

**Manu Vanaerschot**



**PROMOTERS**

Prof. Dr. Jean-Claude Dujardin  
Prof. Dr. Louis Maes

**CO-PROMOTER**

Dr. Saskia Decuyper

Faculty of Pharmaceutical, Biomedical  
and Veterinary Sciences  
Department of Biomedical Sciences  
Antwerpen 2011



**Universiteit  
Antwerpen**



Department of Biomedical Sciences  
Molecular Parasitology Unit



Universiteit  
Antwerpen

Faculty of Pharmaceutical, Biomedical  
and Veterinary Sciences

## **SSG-resistance of *Leishmania (Leishmania) donovani***

**relation with fitness of the parasite and influence on other treatments**

Dissertation for the degree of 'Doctor in Biomedical Sciences'  
at the University of Antwerp to be defended by

**Manu VANAERSCHOT**

19 December 2011, Antwerp

**Promoters:**  
**Prof. Dr. Jean-Claude Dujardin**  
**Prof. Dr. Louis Maes**

**Co-promoter:**  
**Dr. Saskia Decuypere**

## **Doctoral committee**

### **Promoters**

Prof. Dr. Jean-Claude Dujardin

Prof. Dr. Louis Maes

### **Supervisor**

Dr. Saskia Decuyper

### **Chair**

Prof. Dr. Wim Vanden Berghe

### **Member**

Prof. Dr. Paul Cos

Prof. Dr. Marc Coosemans

### **External jury members**

Prof. Dr. Gerald Späth

Prof. Dr. Denis Sereno

### **Cover**

Front: A typical visceral leishmaniasis endemic village in the Siraha District in Eastern Nepal.

Back: In Nepal, visceral leishmaniasis is mainly endemic in the South-Eastern Terai region, a large flat area just before the foothills of the Himalaya Mountains.

### **Dutch title**

SSG-resistentie van *Leishmania (Leishmania) donovani*: relatie met fitness van de parasiet en invloed op andere behandelingen.

## Table of contents

<b>Title page</b>	i
<b>Doctoral committee</b>	ii
<b>Table of contents</b>	iii
<b>Acknowledgements</b>	xii
<b>Summary</b>	xv
<b>Samenvatting</b>	xix
<b>List of abbreviations</b>	xxiii
<b>Chapter 1: <i>Leishmania</i> and Leishmaniasis</b>	3
1.1. Introduction	3
1.2. Taxonomy, diseases and geographical distribution	3
1.3. Transmission	6
1.3.1. General life cycle	6
1.3.2. Transmission patterns	8
1.4. Visceral leishmaniasis in the Indian subcontinent	8
1.4.1. Epidemiology	8
1.4.1.1. Current situation and history	8
1.4.1.2. Socio-economic context	10
1.4.2. Clinical profile	10
1.5. VL diagnosis in the Indian subcontinent	11
1.5.1. Microscopical examination of clinical samples	11
1.5.2. Serological tests	11
1.5.2.1. Antigen detection	11
1.5.2.2. Antibody detection	12

## Table of contents

1.5.3. PCR	13
1.6. VL treatment in the Indian subcontinent	13
1.6.1. Pentavalent antimonials	13
1.6.2. Amphotericin B	14
1.6.2.1. Amphotericin B deoxycholate	14
1.6.2.2. Lipid formulas of amphotericin B	14
1.6.3. Miltefosine	15
1.6.4. Paromomycin	16
1.6.5. Combination therapy	18
1.7. VL control in the Indian subcontinent	19
1.7.1. Options	19
1.7.2. The Kala-azar Elimination Programme in the Indian subcontinent	20
1.8. Survival of <i>Leishmania donovani</i>	22
1.8.1. The host's response against intracellular invaders	23
1.8.2. Preventive strategies of <i>Leishmania</i>	23
1.8.3. Defensive capacities of <i>Leishmania</i>	25
1.9. References	27
 <b>Chapter 2: Sodium stibogluconate in the Indian subcontinent</b>	 <b>45</b>
2.1. The historic journey towards SSG	45
2.2. Efficacy of SSG	46
2.2.1. The gradual decline	46
2.2.2. Treatment failure and drug resistance	47
2.2.3. Detection of SSG-resistance	47
2.3. Action mechanism of SSG	48
2.3.1. Direct action mechanism through Sb <sup>III</sup>	49
2.3.1.1. Sb <sup>V</sup> to Sb <sup>III</sup> reduction	49
2.3.1.2. Influx of antimonials	50
2.3.1.3. Antileishmanial effect of Sb <sup>III</sup>	50

2.3.2. Indirect action mechanism through stimulating the host cell	51
2.4. Molecular mechanisms of SSG-resistance	52
2.4.1. Resistance to the direct action mechanism of SSG through Sb <sup>III</sup>	52
2.4.1.1. Activation-related	53
2.4.1.2. Influx, efflux and target related	53
2.4.2. Resistance to the indirect action mechanism through the host cell	55
2.4.3. Other possible resistance mechanisms	55
2.5. References	57
<b>Chapter 3: Rationale, hypothesis and objectives</b>	<b>69</b>
<b>Chapter 4: <i>In vitro</i> and <i>in vivo</i> characterisation of natural antimonial-sensitive and –resistant <i>Leishmania donovani</i> model strains</b>	<b>75</b>
4.1. Abstract	75
4.2. Introduction	75
4.3. Materials and methods	76
4.3.1. Patients and parasites	76
4.3.2. <i>In vitro</i> promastigote cultures	77
4.3.3. <i>In vitro</i> promastigote growth profile and starvation tests	77
4.3.4. <i>In vitro</i> promastigote stress tests	77
4.3.5. <i>In vitro</i> amastigote infection and stress tests	78
4.3.6. <i>In vivo</i> infection and sampling	79
4.3.7. Tissue lysis and DNA extraction	79
4.3.8. Real-time quantitative PCR and analysis	79
4.4. Results and discussion	80
4.4.1. <i>In vitro</i> promastigote tests	80
4.4.1.1. Growth profile	80
4.4.1.2. Starvation and temperature stress	82
4.4.1.3. Oxidative, nitrosative and metal stress	82

Table of contents

4.4.2. <i>In vitro</i> amastigote tests	84
4.4.2.1. <i>In vitro</i> stresses	84
4.4.2.2. <i>In vitro</i> infectivity	86
4.4.3. <i>In vivo</i> growth profile	87
4.5. Conclusion	89
4.6. References	90
<b>Chapter 5: Antimonial resistance in <i>Leishmania donovani</i> is associated with increased <i>in vivo</i> parasite burden</b>	<b>97</b>
5.1. Abstract	97
5.2. Introduction	97
5.3. Materials and Methods	98
5.3.1. Ethical statements	98
5.3.2. Parasites	98
5.3.3. <i>In vitro</i> promastigote growth	99
5.3.4. Metacyclogenesis assessment	99
5.3.5. <i>In vivo</i> infections	99
5.3.6. Quantification of parasite load	100
5.3.7. kDNA PCR-RFLP	100
5.4. Results	101
5.4.1. <i>In vitro</i> promastigote growth	101
5.4.2. Metacyclogenesis assessment	101
5.4.3. <i>In vivo</i> parasite burden	102
5.4.4. Mixed infection	102
5.5. Discussion	104
5.6. References	106

<b>Chapter 6: Genetic markers for SSG-resistance in <i>Leishmania donovani</i> and SSG-treatment failure in visceral leishmaniasis patients in the Indian subcontinent</b>	<b>111</b>
6.1. Abstract	111
6.2. Introduction	111
6.3. Materials and methods	113
6.3.1. Ethical statements	113
6.3.2. Parasites	113
6.3.3. SNP selection	114
6.3.4. SNP detection	114
6.4. Results	116
6.4.1. Markers for <i>in vitro</i> SSG-resistance of the parasite	116
6.4.2. Markers for SSG-treatment outcome of the patient	118
6.5. Discussion	120
6.6. References	123
<b>Chapter 7: Current miltefosine efficacy in the Indian subcontinent and the future of antimonial-resistant <i>Leishmania donovani</i> populations</b>	<b>129</b>
7.1. Abstract	129
7.2. Introduction	129
7.3. Materials and methods	130
7.3.1. Ethical statements	130
7.3.2. Parasites	130
7.3.3. <i>In vitro</i> MIL-susceptibility test	131
7.3.4. Detection of markers for SSG-treatment failure	131
7.3.5. <i>In vivo</i> animal infections, MIL-treatment and quantification of parasite load in mice	132
7.4. Results	132
7.4.1. <i>In vitro</i> MIL-susceptibility of strains from MIL-treated patients	132
7.4.2. <i>In vivo</i> efficacy of MIL on SSG-S and SSG-R strains isolated in the SSG-era	133

Table of contents

7.4.3. Frequency of the studied genotypes in the SSG- and MIL-era	134
7.5. Discussion	137
7.6. References	139
<b>Chapter 8: Discussion – The fitness of SSG-R <i>Leishmania donovani</i> in the Indian subcontinent</b>	<b>145</b>
8.1. Introduction	145
8.1.1. Drug resistance and disease control	145
8.1.2. Pathogen drug-resistance, fitness and virulence	146
8.2. Relative fitness of SSG-R versus SSG-S <i>L. donovani</i>	147
8.2.1. Overview of the experimental evidence	147
8.2.2. Impact of the genetic background of <i>L. donovani</i> on SSG-resistance and its related fitness	150
8.2.3. Possible mechanisms underlying the higher fitness of SSG-R <i>L. donovani</i>	151
8.3. Impact in the field	152
8.4. Future research perspectives	153
8.5. General conclusion	155
8.6. References	156
<b>Appendix 1: Curriculum Vitae</b>	<b>161</b>
<b>Appendix 2: Licences for use of figures</b>	<b>165</b>

Table of contents

7.4.3. Frequency of the studied genotypes in the SSG- and MIL-era	134
7.5. Discussion	137
7.6. References	139
<b>Chapter 8: Discussion – The fitness of SSG-R <i>Leishmania donovani</i> in the Indian subcontinent</b>	<b>145</b>
8.1. Introduction	145
8.1.1. Drug resistance and disease control	145
8.1.2. Pathogen drug-resistance, fitness and virulence	146
8.2. Relative fitness of SSG-R versus SSG-S <i>L. donovani</i>	147
8.2.1. Overview of the experimental evidence	147
8.2.2. Impact of the genetic background of <i>L. donovani</i> on SSG-resistance and its related fitness	150
8.2.3. Possible mechanisms underlying the higher fitness of SSG-R <i>L. donovani</i>	151
8.3. Impact in the field	152
8.4. Future research perspectives	153
8.5. General conclusion	155
8.6. References	156
<b>Appendix 1: Curriculum Vitae</b>	<b>161</b>
<b>Appendix 2: Licences for use of figures</b>	<b>165</b>